Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-02-07

AUTHORS

Gian Paolo Fadini, Olga Disoteo, Riccardo Candido, Paolo Di Bartolo, Luigi Laviola, Agostino Consoli

ABSTRACT

IntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as > 66% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules. More... »

PAGES

781-800

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2

DOI

http://dx.doi.org/10.1007/s13300-021-01012-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1135197350

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33550569


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5608.b", 
          "name": [
            "Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fadini", 
        "givenName": "Gian Paolo", 
        "id": "sg:person.01122137075.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122137075.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Disoteo", 
        "givenName": "Olga", 
        "id": "sg:person.010554524053.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554524053.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Candido", 
        "givenName": "Riccardo", 
        "id": "sg:person.01026702544.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Bartolo", 
        "givenName": "Paolo", 
        "id": "sg:person.0706015255.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706015255.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7644.1", 
          "name": [
            "Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laviola", 
        "givenName": "Luigi", 
        "id": "sg:person.01354727540.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354727540.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412451.7", 
          "name": [
            "Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Consoli", 
        "givenName": "Agostino", 
        "id": "sg:person.01117461427.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117461427.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12325-018-0868-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111099911", 
          "https://doi.org/10.1007/s12325-018-0868-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00715-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122193928", 
          "https://doi.org/10.1007/s13300-019-00715-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00735-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123468257", 
          "https://doi.org/10.1007/s13300-019-00735-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0452-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104347182", 
          "https://doi.org/10.1007/s13300-018-0452-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0624-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113668568", 
          "https://doi.org/10.1007/s13300-019-0624-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-015-0142-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048653953", 
          "https://doi.org/10.1007/s13300-015-0142-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00725-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123157757", 
          "https://doi.org/10.1007/s13300-019-00725-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-02-07", 
    "datePublishedReg": "2021-02-07", 
    "description": "IntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as >\u200966% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-021-01012-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "GLP-1RAs", 
      "basal insulin", 
      "plasma glucose", 
      "glucagon-like peptide-1 receptor agonists", 
      "insulin glargine/lixisenatide", 
      "peptide-1 receptor agonists", 
      "insulin degludec/liraglutide", 
      "agonist combination therapy", 
      "degludec/liraglutide", 
      "postprandial plasma glucose", 
      "treatment intensification strategies", 
      "use of sulfonylureas", 
      "fixed-dose combination", 
      "type 2 diabetes", 
      "control of glycaemia", 
      "insulin combinations", 
      "treatment intensification", 
      "oral therapy", 
      "nocturnal hypoglycaemia", 
      "glycaemic control", 
      "cardiovascular risk", 
      "postprandial hyperglycaemia", 
      "oral treatment", 
      "diabetes specialists", 
      "BI therapy", 
      "combination therapy", 
      "glycated hemoglobin", 
      "receptor agonist", 
      "IntroductionThe aim", 
      "Delphi consensus", 
      "body weight", 
      "type 2", 
      "level of agreement", 
      "MethodsThe authors", 
      "therapy", 
      "valuable option", 
      "insulin", 
      "best option", 
      "Delphi questionnaire", 
      "Likert scale", 
      "failure", 
      "glucose", 
      "options", 
      "lixisenatide", 
      "liraglutide", 
      "hyperglycaemia", 
      "hypoglycaemia", 
      "ResultsConsensus", 
      "regimen", 
      "glycaemia", 
      "patients", 
      "diabetes", 
      "consensus", 
      "compliance", 
      "agonists", 
      "sulfonylureas", 
      "hemoglobin", 
      "treatment", 
      "panel", 
      "risk", 
      "control", 
      "intensification strategies", 
      "questionnaire", 
      "subjects", 
      "GLP", 
      "combination", 
      "items", 
      "aim", 
      "use", 
      "specialists", 
      "target", 
      "levels", 
      "addition", 
      "weight", 
      "strategies", 
      "study", 
      "survey", 
      "presence", 
      "rounds", 
      "scale", 
      "Delphi", 
      "authors", 
      "statements", 
      "molecules", 
      "definition", 
      "disagreeing", 
      "intensification", 
      "advantages", 
      "agreement", 
      "bots"
    ], 
    "name": "Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies", 
    "pagination": "781-800", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1135197350"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-021-01012-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33550569"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-021-01012-2", 
      "https://app.dimensions.ai/details/publication/pub.1135197350"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_913.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-021-01012-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      22 PREDICATES      123 URIs      108 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-021-01012-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ne9ffc075462f451597e3c9e7d5d8c7e5
4 schema:citation sg:pub.10.1007/s12325-018-0868-9
5 sg:pub.10.1007/s13300-015-0142-y
6 sg:pub.10.1007/s13300-018-0452-y
7 sg:pub.10.1007/s13300-019-00715-x
8 sg:pub.10.1007/s13300-019-00725-9
9 sg:pub.10.1007/s13300-019-00735-7
10 sg:pub.10.1007/s13300-019-0624-4
11 schema:datePublished 2021-02-07
12 schema:datePublishedReg 2021-02-07
13 schema:description IntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as > 66% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N12b1ea8382244314a4f214beda2afe1d
18 N5497f9079419443dbd880a36ae6f2be1
19 sg:journal.1044057
20 schema:keywords BI therapy
21 Delphi
22 Delphi consensus
23 Delphi questionnaire
24 GLP
25 GLP-1RAs
26 IntroductionThe aim
27 Likert scale
28 MethodsThe authors
29 ResultsConsensus
30 addition
31 advantages
32 agonist combination therapy
33 agonists
34 agreement
35 aim
36 authors
37 basal insulin
38 best option
39 body weight
40 bots
41 cardiovascular risk
42 combination
43 combination therapy
44 compliance
45 consensus
46 control
47 control of glycaemia
48 definition
49 degludec/liraglutide
50 diabetes
51 diabetes specialists
52 disagreeing
53 failure
54 fixed-dose combination
55 glucagon-like peptide-1 receptor agonists
56 glucose
57 glycaemia
58 glycaemic control
59 glycated hemoglobin
60 hemoglobin
61 hyperglycaemia
62 hypoglycaemia
63 insulin
64 insulin combinations
65 insulin degludec/liraglutide
66 insulin glargine/lixisenatide
67 intensification
68 intensification strategies
69 items
70 level of agreement
71 levels
72 liraglutide
73 lixisenatide
74 molecules
75 nocturnal hypoglycaemia
76 options
77 oral therapy
78 oral treatment
79 panel
80 patients
81 peptide-1 receptor agonists
82 plasma glucose
83 postprandial hyperglycaemia
84 postprandial plasma glucose
85 presence
86 questionnaire
87 receptor agonist
88 regimen
89 risk
90 rounds
91 scale
92 specialists
93 statements
94 strategies
95 study
96 subjects
97 sulfonylureas
98 survey
99 target
100 therapy
101 treatment
102 treatment intensification
103 treatment intensification strategies
104 type 2
105 type 2 diabetes
106 use
107 use of sulfonylureas
108 valuable option
109 weight
110 schema:name Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
111 schema:pagination 781-800
112 schema:productId N99f6747d754d444c957b65d7f75b9045
113 Nb180ad2162eb4ad996d9bc50eb907c03
114 Nf3e8b1274efd4095b0fa4cdb51619bab
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135197350
116 https://doi.org/10.1007/s13300-021-01012-2
117 schema:sdDatePublished 2022-05-10T10:29
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nef6e3f7e40c0488eb0c15866defc4376
120 schema:url https://doi.org/10.1007/s13300-021-01012-2
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N12b1ea8382244314a4f214beda2afe1d schema:volumeNumber 12
125 rdf:type schema:PublicationVolume
126 N2d346c84e32e482a87cfdac0189bca53 rdf:first sg:person.01026702544.26
127 rdf:rest N8597591a7f2945a3a99023482cd14ac8
128 N5497f9079419443dbd880a36ae6f2be1 schema:issueNumber 3
129 rdf:type schema:PublicationIssue
130 N84f60047e6d6494f80ad7f5519b8746c rdf:first sg:person.010554524053.41
131 rdf:rest N2d346c84e32e482a87cfdac0189bca53
132 N8597591a7f2945a3a99023482cd14ac8 rdf:first sg:person.0706015255.97
133 rdf:rest Nefede7b034fd48c8ab0c47f6a1b9ac59
134 N8925ba6b822f4c4e965b3ffd479afb6a rdf:first sg:person.01117461427.40
135 rdf:rest rdf:nil
136 N99f6747d754d444c957b65d7f75b9045 schema:name dimensions_id
137 schema:value pub.1135197350
138 rdf:type schema:PropertyValue
139 Nb180ad2162eb4ad996d9bc50eb907c03 schema:name doi
140 schema:value 10.1007/s13300-021-01012-2
141 rdf:type schema:PropertyValue
142 Ne9ffc075462f451597e3c9e7d5d8c7e5 rdf:first sg:person.01122137075.78
143 rdf:rest N84f60047e6d6494f80ad7f5519b8746c
144 Nef6e3f7e40c0488eb0c15866defc4376 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 Nefede7b034fd48c8ab0c47f6a1b9ac59 rdf:first sg:person.01354727540.43
147 rdf:rest N8925ba6b822f4c4e965b3ffd479afb6a
148 Nf3e8b1274efd4095b0fa4cdb51619bab schema:name pubmed_id
149 schema:value 33550569
150 rdf:type schema:PropertyValue
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1044057 schema:issn 1869-6953
158 1869-6961
159 schema:name Diabetes Therapy
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01026702544.26 schema:affiliation grid-institutes:None
163 schema:familyName Candido
164 schema:givenName Riccardo
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26
166 rdf:type schema:Person
167 sg:person.010554524053.41 schema:affiliation grid-institutes:None
168 schema:familyName Disoteo
169 schema:givenName Olga
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554524053.41
171 rdf:type schema:Person
172 sg:person.01117461427.40 schema:affiliation grid-institutes:grid.412451.7
173 schema:familyName Consoli
174 schema:givenName Agostino
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117461427.40
176 rdf:type schema:Person
177 sg:person.01122137075.78 schema:affiliation grid-institutes:grid.5608.b
178 schema:familyName Fadini
179 schema:givenName Gian Paolo
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122137075.78
181 rdf:type schema:Person
182 sg:person.01354727540.43 schema:affiliation grid-institutes:grid.7644.1
183 schema:familyName Laviola
184 schema:givenName Luigi
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354727540.43
186 rdf:type schema:Person
187 sg:person.0706015255.97 schema:affiliation grid-institutes:None
188 schema:familyName Di Bartolo
189 schema:givenName Paolo
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706015255.97
191 rdf:type schema:Person
192 sg:pub.10.1007/s12325-018-0868-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111099911
193 https://doi.org/10.1007/s12325-018-0868-9
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s13300-015-0142-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1048653953
196 https://doi.org/10.1007/s13300-015-0142-y
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s13300-018-0452-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1104347182
199 https://doi.org/10.1007/s13300-018-0452-y
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s13300-019-00715-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1122193928
202 https://doi.org/10.1007/s13300-019-00715-x
203 rdf:type schema:CreativeWork
204 sg:pub.10.1007/s13300-019-00725-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123157757
205 https://doi.org/10.1007/s13300-019-00725-9
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s13300-019-00735-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123468257
208 https://doi.org/10.1007/s13300-019-00735-7
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s13300-019-0624-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113668568
211 https://doi.org/10.1007/s13300-019-0624-4
212 rdf:type schema:CreativeWork
213 grid-institutes:None schema:alternateName Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy
214 Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
215 Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy
216 schema:name Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy
217 Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
218 Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy
219 rdf:type schema:Organization
220 grid-institutes:grid.412451.7 schema:alternateName Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy
221 schema:name Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy
222 rdf:type schema:Organization
223 grid-institutes:grid.5608.b schema:alternateName Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy
224 schema:name Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy
225 rdf:type schema:Organization
226 grid-institutes:grid.7644.1 schema:alternateName Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy
227 schema:name Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...